Business Context and Reporting Period
Compugen Ltd., a drug and diagnostic discovery company, reported financial results for the second quarter ended June 30, 2005, via a Form 6-K filed on July 27, 2005. The company focuses on predictive models and discovery engines to develop therapeutic products and diagnostic markers.
Key Financial Metrics
| Metric | Q2 2005 | Q2 2004 | YTD 2005 | YTD 2004 |
|---|---|---|---|---|
| Total Revenues and Grants | $474,000 | $984,000 | $1.3 million | $2.5 million |
| Net Loss | $3.3 million | $3.4 million | $7.1 million | $6.4 million |
| Net Loss Per Share | $0.12 | $0.12 | $0.25 | $0.23 |
| Cash and Marketable Securities | $41.0 million (as of June 30, 2005) | N/A | N/A | N/A |
Revenue Composition (Q2 2005): Total revenue included $70,000 in product revenues and $404,000 in governmental and other grants.
Liquidity: As of June 30, 2005, the company held $41.0 million in cash, cash equivalents, and marketable securities, representing a decrease of $2.5 million from March 31, 2005.
Material Changes Versus Prior Period
- Revenue Decline: Total revenues and grants for Q2 2005 decreased by approximately 52% compared to Q2 2004, driven primarily by a drop in product revenues from $707,000 to $70,000, partially offset by an increase in grants.
- Expense Reduction: Total operating expenses decreased from $4.8 million in Q2 2004 to $4.2 million in Q2 2005. This reduction was largely due to a shift from a $131,000 non-cash expense for amortization of deferred compensation in 2004 to a $9,000 non-cash income in 2005.
- Net Loss: Despite lower expenses, the net loss remained relatively flat at $3.3 million for Q2 2005 compared to $3.4 million in Q2 2004.
Outlook, Management Commentary, and Risks
Management Commentary: CEO Mor Amitai highlighted the company's decade-long focus on discovery capabilities. He noted the signing of three milestone and royalty-bearing pipeline agreements with major diagnostic companies in the last ten months, signaling commercial potential.
Forward-Looking Statements: The filing includes standard warnings regarding risks such as changes in collaborator relationships, competitive products, technological changes, and the ability to implement technological improvements.
Unusual Items: The financial results include non-cash items related to the amortization of deferred compensation, which fluctuated between an expense in 2004 and income in 2005.
Investor Verification Checklist
- Verify the sustainability of the $404,000 in governmental and other grants received in Q2 2005, as product revenues dropped significantly to $70,000.
- Confirm the status and expected revenue contribution of the three pipeline agreements mentioned by management.
- Monitor the burn rate given the $2.5 million decrease in cash and marketable securities between March and June 2005.
- Review the impact of non-cash deferred compensation adjustments on reported net loss figures.